Gene News and Research

Latest Gene News and Research

Study finds genetic variants that may modify breast cancer risk among women with BRCA2 mutation

An international study led by researchers at Memorial Sloan-Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer. The study was published today online in the open-access journal PLoS Genetics.

29 Oct 2010

Nanomedicine Center for Nucleoprotein Machines receives $16.1 million NIH award

The Georgia Tech-led Nanomedicine Center for Nucleoprotein Machines has received an award of $16.1 million for five years as part of its renewal by the National Institutes of Health (NIH). The eight-institution research team plans to pursue development of a clinically viable gene correction technology for single-gene disorders and demonstrate the technology's efficacy with sickle cell disease.

29 Oct 2010

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

After receiving a priority review, Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved SPRYCEL (dasatinib) 100 mg once daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.

29 Oct 2010

New approach for early diagnosis of pancreatic cancer

Pancreatic tumors are one of the most lethal cancers, with fewer than five percent of patients surviving five years after diagnosis. But a new study that peers deeply into the genetics of pancreatic cancer presents a bit of good news an opportunity for early diagnosis. In contrast to earlier predictions, many pancreatic tumors are, in fact, slow growing, taking nearly 20 years to become lethal after the first genetic perturbations appear.

29 Oct 2010

DiaGenic third quarter income increases from NOK -9.3 million to NOK -9.6 million

DiaGenic: The interim report for the third quarter 2010 was approved by the Board of Directors on 28 October 2010.

29 Oct 2010

Researchers develop morpholino oligonucleotides that can turn off specific genes

Researchers at North Carolina State University have found a way to "cage" genetic off switches in such a way that they can be activated when exposed to UV light. Their technology gives scientists a more precise way to control and study gene function in localized areas of developing organisms.

29 Oct 2010

Prominent scientist in mitochondrial genetics joins Children's Hospital to establish CMEM

Douglas C. Wallace, Ph.D., a pioneer and internationally prominent scientist in the field of human mitochondrial genetics, has joined The Children's Hospital of Philadelphia to continue his investigations into the role of mitochondrial energy in health and disease.

29 Oct 2010

Scientists identify potential new treatment for Nipah and Hendra viruses

Scientists at Weill Cornell Medical College have identified a potential new treatment for the Nipah and Hendra viruses, two lethal and emerging viruses for which there is currently no treatment or vaccine available. The approach could also lead to new therapies for measles, mumps and the flu. The new research appears in today's edition of the prestigious journal Public Library of Science (PLoS) Pathogens.

29 Oct 2010

Regulus receives $10M equity investment from sanofi-aventis

Regulus Therapeutics Inc. announced today that the Company has received a $10 million equity investment from sanofi-aventis in connection with the landmark alliance the two companies entered into on June 21, 2010. The equity investment by sanofi-aventis further strengthens the balance sheet of Regulus, and with this investment sanofi-aventis becomes the third investor in Regulus, along with its founding companies Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc..

29 Oct 2010

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

The U.S. Food and Drug Administration today approved a new indication for Sprycel (dasatinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality.

29 Oct 2010

Inefficient suppression of DUX4 gene causes facioscapulohumeral dystrophy: Study

An international team of researchers led by an investigator from Fred Hutchinson Cancer Research Center has made a second critical advance in determining the cause of a common form of muscular dystrophy known as facioscapulohumeral dystrophy, or FSHD.

29 Oct 2010

StemCells initiates HuCNS-SC second clinical trial for Batten disease in children

StemCells, Inc. announced today that it has initiated a second clinical trial of its HuCNS-SC product candidate (purified human neural stem cells) in neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease), a fatal neurodegenerative disorder in children.

29 Oct 2010

Pain Therapeutics third quarter net loss decreases from $1.3 million to $1.0 million

Pain Therapeutics, Inc. a biopharmaceutical company, today reported financial results for its third quarter of fiscal year 2010.

29 Oct 2010

Common psychiatric drugs could slow dementia

Researchers say commonly used psychiatric drugs could be effective in slowing the progression of certain types of dementia. Dr John Kwok and colleagues from Neuroscience Research Australia have discovered a mutant gene that causes abnormal proteins build up in the brains of people with frontotemporal dementia, a disease that affects people in their 50s and 60s.

28 Oct 2010

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

Celgene Corporation announced non-GAAP net income of $349.9 million, or non-GAAP diluted earnings per share of $0.75 for the quarter ended September 30, 2010.

28 Oct 2010

QLT expands QLT091001 Phase 1b LCA study to include patients with Retinitis Pigmentosa

QLT Inc. today announced expansion of the Phase 1b clinical proof-of-concept study of QLT091001 in the treatment of Leber Congenital Amaurosis (LCA) to include patients with Retinitis Pigmentosa (RP), a set of hereditary retinal diseases demonstrating clinical features similar to LCA.

28 Oct 2010

World's largest research initiative to mutate all mouse genes

The world's largest research initiative to mutate all mouse genes is now able to reach the summit because the ambitious EUCOMMTOOLS project started on October 1, 2010. This project is being coordinated by Helmholtz Zentrum München and will finalize the groundwork for the analysis of all mouse gene functions. The findings will contribute to a better understanding of the pathogenesis of widespread diseases such as Alzheimer's, depression, diabetes, chronic lung diseases or cancer.

28 Oct 2010

USPTO rejects patent claims asserted against Precision BioSciences

Precision BioSciences, Inc., today announced that the United States Patent and Trademark Office (PTO) has issued Final Decisions and Right of Appeal Notices in the reexamination proceedings for U.S. Pat. Nos. 6,833252, 7,214,536, 6,610,545 and 7,309,605 that are owned by the Institut Pasteur and the Universite Pierre et Marie Curie, and licensed to Cellectis, SA (ALCLS).

28 Oct 2010

Pfizer announces publication of crizotinib data for NSCLC patients in New England Journal of Medicine

Pfizer Inc. announced today the publication of data showing that 57 percent of ALK-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib (PF-02341066), an investigational oral anaplastic lymphoma kinase (ALK) inhibitor, had either a complete (one patient) or partial (46 patients) response to treatment. Data from 82 patients in this Part 2 expansion cohort of the Phase 1 study were published in the October 28 issue of the New England Journal of Medicine.

28 Oct 2010

AnaptysBio announces issuance of two new patents for SHM-XEL platform

AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, announced the issuance of patents in the US and Europe that provide additional coverage for its SHM-XEL platform. These patents extend AnaptysBio's leadership in the use of somatic hypermutation (SHM) for the discovery and optimization of antibodies and other proteins.

28 Oct 2010

Gene News and Research

Latest Gene News and Research

Study finds genetic variants that may modify breast cancer risk among women with BRCA2 mutation

Nanomedicine Center for Nucleoprotein Machines receives $16.1 million NIH award

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

New approach for early diagnosis of pancreatic cancer

DiaGenic third quarter income increases from NOK -9.3 million to NOK -9.6 million

Researchers develop morpholino oligonucleotides that can turn off specific genes

Prominent scientist in mitochondrial genetics joins Children's Hospital to establish CMEM

Scientists identify potential new treatment for Nipah and Hendra viruses

Regulus receives $10M equity investment from sanofi-aventis

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

Inefficient suppression of DUX4 gene causes facioscapulohumeral dystrophy: Study

StemCells initiates HuCNS-SC second clinical trial for Batten disease in children

Pain Therapeutics third quarter net loss decreases from $1.3 million to $1.0 million

Common psychiatric drugs could slow dementia

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

QLT expands QLT091001 Phase 1b LCA study to include patients with Retinitis Pigmentosa

World's largest research initiative to mutate all mouse genes

USPTO rejects patent claims asserted against Precision BioSciences

Pfizer announces publication of crizotinib data for NSCLC patients in New England Journal of Medicine

AnaptysBio announces issuance of two new patents for SHM-XEL platform

eBook: Using iPSCs models for human disease research and drug discovery eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey